Clinical Trial Update: A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 study update of a recombinant anti-IL-17A monoclonal antibody in Chinese patients with moderate-to-severe psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Recombinant anti-IL-17A humanized monoclonal antibody

Snippet

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Conditions: Psoriasis | Phase 2 | Status: UNKNOWN